Rafael Holdings Reports $29.6 Million Annual Loss
The Newark firm faces significant going-concern risks as it manages high R&D costs and pending drug application approvals.
Live Poll
Do you trust biotechnology companies to succeed despite recent financial losses and failed clinical trials?